Purpose: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve survival in select patients with gastric cancer and peritoneal metastases. It remains unclear, however, whether this multimodal treatment protocol is also beneficial for signet-ring cell gastric cancer (SRC) patients with peritoneal metastases. Results: Eighteen consecutive patients for whom irresectability has been ruled out by a computed tomography scan were enrolled. However, complete cytoreduction could only be achieved in 72% of patients. When categorizing patients with respect to the completeness of cytoreduction, we found no difference between both groups considering tumor-or patient-related factors. The overall complication rate following complete cytoreduction and HIPEC was 46%. Within a median follow-up of 6.6 (0.5~31) months, the median survival for CRS and HIPEC patients was 8.9 months as opposed to 1.1 months for patients where complete cytoreduction could not be achieved. Following complete cytoreduction and HIPEC, progression-free survival was 6.2 months. Conclusions: In SRC with peritoneal metastases, the prognosis appears to remain poor irrespective of complete CRS and HIPEC. Moreover, complete cytoreduction could not be achieved in a considerable percentage of patients. In SRC, CRS and HIPEC should be restricted to highly selective patients in order to avoid exploratory laparotomy.
Introduction
In early stage (T1 and T2) gastric cancer, surgical resection represents definitive treatment, with 5-year survival rates ranging 70% to 95%. 1, 2 In locally advanced tumors, however, prognosis is poor despite curative resection and extended lymphadenectomy.
1,2
As a consequence, multimodal treatment strategies that consist of pre-and postoperative chemotherapy and aim for enhanced local control and improved survival have been established.
Peritoneal metastases in gastric cancer are considered to indicate terminal disease. Therapy is mainly based on palliative chemotherapy with poor long-term survival because systemic chemotherapy is unlikely to accumulate in peritoneal nodules in cytotoxic concentrations. [3] [4] [5] [6] [7] [8] Cytoreductive surgery (CRS) along with hyperthermic intraperitoneal chemotherapy (HIPEC) has been suggested to improve survival in select patients with limited peritoneal spread, resulting in a median overall survival (OS) of 8 to 14 months. [8] [9] [10] It remains unclear, however, whether preoperative chemotherapy might be able to add additional oncological benefits without disproportionately raising adverse events. So far, only few clinical studies evaluated this particular treatment protocol. [8] [9] [10] In particular, data on the management of signet-ring cell cancers with peritoneal metastases are still lacking in the current literature.
Signet-ring cell gastric cancer (SRC) is associated with poor outcome and its response to systemic chemotherapy is low. To date, it remains unclear why SRC patients tend to primarily experience peritoneal tumor spread and why their response to systemic chemotherapy is usually poor. 11, 12 On the basis of the low response rates to systemic chemotherapy and the lack of treatment alternatives, radical surgery with HIPEC is discussed with each patient individually as a personalized approach.
With this retrospective analysis, we sought to investigate whether preoperative chemotherapy followed by CRS and HIPEC could also be performed in SRC patients with peritoneal metastases with acceptable morbidity and mortality.
Materials and Methods 
Upfront chemotherapy protocol
The neoadjuvant chemotherapy protocol consisted of 4 to 6 cy- 
Surgical procedure
After laparotomy through a mid-line incision and complete adhesiolysis, the peritoneal carcinomatosis index (PCI) was determined following the criteria described by Jacquet and Sugarbaker. 
Statistics
Data are presented as median (minimum~maximum) or number (%) unless otherwise stated. Qualitative differences were compared using the χ 2 -test and quantitative differences were assessed using the Mann-Whitney U test. Survival analysis was performed by the Kaplan-Meier method. For OS, the time to the event was calculated as the time from CRS until death or time to last contact, if the patient was alive. Recurrence was calculated from the date of surgery to the time of relapse, or to the last known date of followup evaluation, or the date of death using the Kaplan-Meier method.
A P-value of less than 0.05 was considered significant. SPSS version 13.0 software (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.
Results

Treatment
Eighteen patients for whom there was radiographical evidence of peritoneal disease without signs of irresectability or distant metastases were scheduled for upfront chemotherapy. Intraoperatively, complete cytoreduction (CC-0 or CC-1) could be achieved in 13 patients (72%), whereas 5 patients (28%) underwent only explorative laparotomy due to either the involvement of the pancreas, or the retraction of the mesenteric axis, or tumor involvement of the small bowel surface. In these particular patients, we found both a significantly higher extent of small bowel involvement as well as a trend towards a more locally advanced tumor growth (Table 1) . In one patient, a palliative gastrectomy was performed due to symptomatic gastric outlet obstruction.
Baseline demographic and intraoperative characteristics are shown in In order to achieve complete cytoreduction, 7 patients (54%) underwent right upper quadrant, 5 patients (38%) left upper quadrant, and 5 patients (38%) pelvic peritonectomy. Additionally, 21 visceral resections were performed. In 46% of patients, however, proximal and/or distal gastric resection margins were histologically positive for tumor involvement (R1-resection) despite complete cytoreduction (Table 3 ).
Morbidity and mortality
The overall complication rate following complete cytoreduction and HIPEC was 46%. There were 11 adverse events (Clavien-Dindo I~IV) in 6 patients. However, there was no anastomotic leakage and no need for any re-operation. In addition, there was no inhospital death. Four patients (31%) experienced mild (＜3,500/ml) temporary HIPEC-related leucopenia. Adverse events are listed in Table 4 .
Postoperative outcome
The median follow-up was 6.6 (0.5~31) months. Within the follow-up period, 6 patients (46%) who underwent complete cyto- Values are presented as median (range) or number (%). HIPEC = hyperthermic intraperitonealchemotherapy; PC = peritoneal metastases; APR = abdomino-pelvic region (according to Sugarbaker). (Fig. 1) .
Following complete CRS and HIPEC, progression-free survival was 6.2 months (Fig. 2) . In 2 patients, the recurrence was located in the parietal peritoneum. One patient experienced a lymph node recurrence. Distant metastases were not observed within the followup period.
Discussion
In our investigation, the incidence of postoperative complications was comparable with available Phase II and III studies. 7-10, 18 Yang et al. 18 reported severe adverse events in 14.7% of patients, and Glehen et al. 8 found major complications in 27.8% of patients. In their case series, Scaringi et al. 7 reported that 10 out of 37 patients developed at least one complication whereas Hultman et al. 9 described grade II~IV adverse events in 62.5% of patients. Our surgery-related morbidity seemed acceptable without any in-hospital deaths, even though several peritonectomy procedures and visceral resections had to be performed per patient to achieve complete cytoreduction.
We observed no anastomotic leakage or duodenal fistula and no re-operations were required. The majority of adverse events were HIPEC-related, such as leucopenia. However, only mild leucopenia was found without any need for granulocyte-colony stimulating factors.
Complete cytoreduction could be achieved in 72% patients. This is in accordance with Yonemura et al. 5 and Hultman et al., 10 who reported a 71% and 44% rate of complete cytoreduction, respectively. 9 However, in 28% of patients radical surgery was As stated above, surgery had to be terminated as explorative laparotomy in 28% of patients because of tumor spread that could not be ruled out by preoperative radiological diagnostics. However, the majority of preoperative CT scans have not been performed in our hospital. Therefore, the precise initial tumor burden as well as the response to chemotherapy could not be evaluated, which is a major limitation of our investigation. Since the hospital stay did not differ between the 2 groups and the outcome was very poor, explorative laparotomy by itself seems to have a negative impact on outcome, emphasizing the need for more appropriate selection criteria. Since there was no difference between the 2 groups with respect to tumor-and patient-related factors, we will in the future use laparoscopy and histology with response evaluation in every patient prior to performing CRS and HIPEC, in order to avoid unnecessary exploratory laparotomy. Due to the synchronous peritoneal spread, laparoscopy is likely to work well because no previous extensive oncologic surgery has been performed in these particular patients. Nonetheless, a meticulous laparoscopic assessment of the entire abdominal cavity remains challenging. However, ruling out patients with tumor progression and histological non-responders should be possible.
This multimodal protocol consisting of upfront chemotherapy, CRS and HIPEC is feasible with acceptable surgical morbidity in highly selective SRC patients with peritoneal metastases. However, survival seems to remain low and complete cytoreduction is not possible in a considerable percentage of patients despite accurate preoperative radiographic diagnostics with exploratory laparotomy, leading to a worse prognosis.
In summary, even though a randomized phase-III study by
Yang et al. 18 suggested that CRS and HIPEC prolong survival in patients with peritoneal metastases from predominantly non-SRC, according to our data, CRS and HIPEC cannot be recommended for patients with SRC and peritoneal metastases in general. Moreover, it seems very likely that only patients with limited peritoneal spread will benefit from this multimodal approach. 19 Therefore, initial staging laparoscopy might help as a selection tool for identifying patients with both high abdominal tumor load and as being unlikely to achieve complete cytoreduction.
We modified our treatment protocol utilizing staging laparosco- 
